We believe that the combination of AFP and PIVKA‐II will improve the diagnosis and the recurrence detection rate of HCC patients, increase the proportion of early treatment, ultimately improve the survival rate and prolong the life of HCC patients. Here, AFP is linked to hepatocellular carcinoma.